Jupiter Topco LLC Purchases Shares of 8,376 Establishment Labs Holdings Inc. $ESTA

Jupiter Topco LLC purchased a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the second quarter, Holdings Channel reports. The fund purchased 8,376 shares of the company’s stock, valued at approximately $719,000.

Several other large investors have also recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Establishment Labs by 20.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock worth $2,335,000 after purchasing an additional 9,557 shares during the period. Geode Capital Management LLC raised its position in Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after purchasing an additional 299 shares during the period. WINTON GROUP Ltd purchased a new stake in Establishment Labs in the second quarter valued at approximately $651,000. Nebula Research & Development LLC raised its position in Establishment Labs by 27.9% in the second quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock valued at $692,000 after purchasing an additional 3,538 shares during the period. Finally, Sei Investments Co. lifted its stake in Establishment Labs by 13.3% during the second quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock worth $2,068,000 after purchasing an additional 5,668 shares in the last quarter. 72.91% of the stock is currently owned by institutional investors and hedge funds.

Establishment Labs Price Performance

Establishment Labs stock opened at $74.29 on Monday. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11. Establishment Labs Holdings Inc. has a 52-week low of $36.53 and a 52-week high of $97.59. The firm has a market cap of $2.21 billion, a PE ratio of -56.71 and a beta of 1.05. The company’s 50 day moving average is $83.45 and its two-hundred day moving average is $74.89.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The business had revenue of $67.54 million during the quarter, compared to analyst estimates of $65.79 million. During the same quarter last year, the firm earned ($0.57) EPS. The business’s revenue was up 31.7% on a year-over-year basis. On average, research analysts expect that Establishment Labs Holdings Inc. will post -1.15 EPS for the current fiscal year.

Analysts Set New Price Targets

ESTA has been the subject of several research analyst reports. JPMorgan Chase & Co. raised their price target on Establishment Labs from $84.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a report on Wednesday, June 24th. TD Cowen increased their target price on Establishment Labs from $95.00 to $117.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. BTIG Research restated a “buy” rating and set a $103.00 target price on shares of Establishment Labs in a report on Tuesday, September 1st. Finally, Canaccord Genuity Group set a $105.00 target price on Establishment Labs in a research report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Establishment Labs currently has an average rating of “Moderate Buy” and an average price target of $100.25.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.